Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
To create leading company developing medicines targeting metalloenzymes
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)
Subscribe To Our Newsletter & Stay Updated
